Foghorn Therapeutics
在场
Foghorn Therapeutics 的所有者是 Flagship Pioneering.
Flagship Pioneering 拥有 22家子公司，其中包括 Alltrna、Apriori Bio 和 Cellaritybio。
他们在：
高管
查看带有其 28 名主要高管的组织结构图
Foghorn Therapeutics 搜索最多的简介
- Adrian Gottschalk, Director, President and Chief Executive Officer
- Thomas Lynch, Director
- Scott Biller, Director
高管在Foghorn Therapeutics变化
- Kristian Humer已作为Chief Financial Officer加入公司 (新闻发布的2024四月17号).
- Allan Reine, Chief Financial Officer, 已经离开公司 (新闻发布的2024一月4号).
高管在Flagship Pioneering变化
- John LeporeJohn Lepore 将于202310月16作为 Chief Executive Officer-Partner and Chief Executive Officer of Profound Therapeutics 加入公司 (新闻发布的2023十月3号).
- Amanda Kay 曾任 Operating Partner and President of Metaphore Biotechnologies, 现升职为 Senior Partner and Chief Business Development Officer (新闻发布的2023九月12号).
创建提醒
跟踪 Foghorn Therapeutics 的高管变动
生物技术
Flagship Pioneering 拥有 2,292 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Lycia Therapeutics 刚刚宣布为 107 筹款数百万美元。 (公布2024五月15号).
- Attovia Therapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2024五月14号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024五月13号).
生物技术 行业的其他推荐联系人
消息
Foghorn Therapeutics 的最新新闻稿
- Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences | Foghorn Therapeutics
- Foghorn Therapeutics Announces Upcoming Investor Conference Participation | Foghorn Therapeutics
- Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS | Foghorn Therapeutics
- Foghorn Therapeutics Provides First Quarter 2022 Corporate Update | Foghorn Therapeutics
- Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting | Foghorn Therapeutics
- Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting | Foghorn Therapeutics
- Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day | Foghorn Therapeutics
- Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook | Foghorn Therapeutics
- Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference | Foghorn Therapeutics
- News | Foghorn Therapeutics
- View more press releases Close
通过电子邮件
